38th Annual Report of the Company
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Bacil Pharma Ltd has submitted the notice for its 38th Annual General Meeting (AGM) along with the Annual Report for the financial year ended March 31, 2025. The AGM will be held on Monday, September 29, 2025 at 1:00 PM through video conferencing. Key business items include adoption of audited financial statements, re-appointment of Ms. Chaitali Kalpataru Shah as Executive Director, appointment of a new Independent Director (Ms. Vivek Mukesh Yadav for a 5-year term), and appointment of a new Statutory Auditor (M/s Sarang Shivajirao Chavan & Associates) to fill the casual vacancy caused by resignation of the previous auditor. The notice also seeks shareholder approval for raising borrowing limits up to ₹100 crore, enabling loans/investments up to ₹100 crore, reclassifying certain outgoing promoters to the public category, and approving raising of funds through loans with an option to convert into equity shares up to ₹50 crore. Several board changes occurred during the year including resignations of two directors and the previous CFO, and appointment of new directors and a new CFO.
This is primarily a procedural filing covering the AGM agenda. The borrowing limit enhancement to ₹100 crore and the option to convert loans into equity shares (up to ₹50 crore) indicate the company may raise additional capital, which could lead to equity dilution. Reclassification of promoters to public category signals a change in promoter status but the overall shareholding remains small. Shareholders should note the September 23-29, 2025 book closure period and the September 24, 2025 cut-off date for e-voting eligibility.